Pfizer Inc
PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Aug 4, 2026Score 11/3053% above fair value
$30.52+0.57 (+1.90%)
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Biopharma Operating Segment by Quarter
Biopharma Operating Segment — Segment Pretax Income / Earnings ($M) ($M)
Pfizer Biopharma Operating Segment: $6,887M in Q2 2026, down 0.1% from a year earlier.
Latest, Q2 2026
6,887
Period ended Jun 28, 2026
Change on a year earlier
-0.1%
6,891 in Q2 2025
History
34 quarters
Since Q1 2018
Sources
26
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-08-04) ↗
Granular segment expense disaggregation adopted under FASB ASU 2023-07 plus corporate reconciling items not in DB segment_values.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Biopharma Operating Segment — Segment Pretax Income / Earnings ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 28, 2026 | 6,887 | -0.1% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2026 | Mar 29, 2026 | 6,838 | -3.3% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 6,913 | +10.4% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2025 | Sep 28, 2025 | 8,469 | +2.4% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2025 | Jun 29, 2025 | 6,891 | +16.9% | Form 10-Q (filed 2026-08-04) ↗ |
| Q1 2025 | Mar 30, 2025 | 7,069 | -7.3% | Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2024 | Dec 31, 2024 | 6,262 | +365.6% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2024 | Sep 29, 2024 | 8,269 | -6,135.8% | Form 10-Q (filed 2025-11-04) ↗ |
| Q2 2024 | Jun 30, 2024 | 5,897 | +17.0% | Form 10-Q (filed 2025-08-05) ↗ |
| Q1 2024 | Mar 31, 2024 | 7,622 | -19.9% | Form 10-Q (filed 2025-05-05) ↗ |
| Q4 2023 | Dec 31, 2023 | 1,345 | -50.5% | Form 10-K (filed 2026-02-26) ↗ |
| Q3 2023 | Oct 1, 2023 | -137 | -100.9% | Form 10-Q (filed 2024-11-04) ↗ |
| Q2 2023 | Jul 2, 2023 | 5,042 | -70.6% | Form 10-Q (filed 2024-08-05) ↗ |
| Q1 2023 | Apr 2, 2023 | 9,517 | -28.9% | Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2022 | Dec 31, 2022 | 2,717 | -74.6% | Form 10-K (filed 2025-02-27) ↗ |
| Q3 2022 | Oct 2, 2022 | 14,665 | +23.8% | Form 10-Q (filed 2023-11-08) ↗ |
| Q2 2022 | Jul 3, 2022 | 17,166 | +74.9% | Form 10-Q (filed 2023-08-09) ↗ |
| Q1 2022 | Apr 3, 2022 | 13,391 | +59.7% | Form 10-Q (filed 2023-05-10) ↗ |
| Q4 2021 | Dec 31, 2021 | 10,695 | +52.7% | Form 10-K (filed 2024-02-22) ↗ |
| Q3 2021 | Oct 3, 2021 | 11,848 | +74.1% | Form 10-Q (filed 2022-11-09) ↗ |
| Q2 2021 | Jul 4, 2021 | 9,816 | +47.6% | Form 10-Q (filed 2022-08-10) ↗ |
| Q1 2021 | Apr 4, 2021 | 8,383 | +24.6% | Form 10-Q (filed 2022-05-11) ↗ |
| Q4 2020 | Dec 31, 2020 | 7,005 | +17.6% | Form 10-K (filed 2023-02-23) ↗ |
| Q3 2020 | Sep 27, 2020 | 6,807 | +4.6% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2020 | Jun 28, 2020 | 6,650 | +9.5% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2020 | Mar 29, 2020 | 6,729 | +14.4% | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2019 | Dec 31, 2019 | 5,958 | +3.6% | Form 10-K (filed 2022-02-24) ↗ |
| Q3 2019 | Sep 29, 2019 | 6,506 | +4.8% | Form 10-Q (filed 2020-11-05) ↗ |
| Q2 2019 | Jun 30, 2019 | 6,071 | +1.9% | Form 10-Q (filed 2020-08-06) ↗ |
| Q1 2019 | Mar 31, 2019 | 5,883 | +1.0% | Form 10-Q (filed 2020-05-07) ↗ |
| Q4 2018 | Dec 31, 2018 | 5,751 | – | Form 10-K (filed 2020-02-27) ↗ |
| Q3 2018 | Sep 30, 2018 | 6,206 | – | Form 10-Q (filed 2019-11-07) ↗ |
| Q2 2018 | Jul 1, 2018 | 5,958 | – | Form 10-Q (filed 2019-08-08) ↗ |
| Q1 2018 | Apr 1, 2018 | 5,823 | – | Form 10-Q (filed 2019-05-09) ↗ |
Breakdown
What makes up biopharma Operating Segment
- Biopharma Segment — Cost of sales (ASU 2023-07 significant expense) ($M)3,188 · Q2 2026
- Biopharma Segment — Selling, informational & administrative expenses ($M)2,344 · Q2 2026
- Biopharma Segment — Research & development expenses ($M)2,376 · Q2 2026
- Biopharma Segment — Acquired in-process R&D (IPR&D) ($M)16 · Q2 2026
- Biopharma Segment — Other (income)/deductions — net ($M)151 · Q2 2026
- Biopharma Segment — Depreciation & amortization ($M)324 · Q2 2026
- Other Business Activities (PC1, Pfizer Ignite) — Revenues ($M)373 · Q2 2026
- Other Business Activities (PC1, R&D platforms & corporate research) — Pretax loss ($M)-1,708 · Q2 2026
- Corporate / Unallocated Reconciling Item — Intangible amortization pretax impact ($M)-1,185 · Q2 2026
- Corporate / Unallocated Reconciling Item — Acquisition-related costs pretax impact ($M)-669 · Q2 2026
- Corporate / Unallocated Reconciling Item — Certain significant & unallocated items ($M)-3,978 · Q2 2026
- Amortization of intangible assets unassociated with segments ($M)1,185 · Q2 2026
Cite this data
StockData. (2026). Pfizer Biopharma Operating Segment ($M), quarterly Q1 2018–Q2 2026 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/seg-ebt-biopharma
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.